Median (IQR) N (%)
Active TB (n=30)
Latent TB (n=88)
NTM infection (n=25)
HIV-TB coinfection (n=64)
Age (yrs)
41 (33-56) 40 (23-63) 66 (57-74) 38 (32-44)
Gender Male 20 (67%) 23 (26%) 10 (40%) 40 (62%)
Female 10 (33%) 65 (74%) 15 (60%) 24 (38%)
Ethnicity African 2 (7%) 7 (8%) 0 (0%) 64 (100%)
Arab 0 (0%) 1 (1%) 0 (0%) 0 (0%)
Bangladeshi 1 (3%) 2 (2%) 0 (0%) 0 (0%)
Indian 7 (23%) 3 (3%) 0 (0%) 0 (0%)
Iraqi 1 (3%) 0 (0%) 0 (0%) 0 (0%)
Pakistani 5 (17%) 3 (3%) 1 (4%) 0 (0%)
South East Asian 2 (7%) 1 (1%) 0 (0%) 0 (0%)
White 12 (40%) 66 (75%) 24 (96%) 0 (0%)
Unknown 0 (0%) 5 (6%) 0 (0%) 0 (0%)
Location of infection Pulmonary 11 (37%) - - 51 (80%)
Extrapulmonary 16 (53%) - - 9 (14%)
Both 3 (10%) - - 1 (1%)
Unknown 0 (0%) - - 3 (5%)
Culture confirmed Yes 20 (67%) - - 64 (100%)
No 10 (33%) - - 0 (0%)
Resistance None 26 (87%) - - -
Isoniazid 1 (3%) - - -
Pyrazinamide 2 (7%) - - -
Rifampicin 0 (0%) - - -
MDR 1 (3%) - - -
NTM species MAC - - 22 (88%) -
M. abscessus - - 2 (8%) -
M. malmoense - - 1 (4%) -
Baseline ALT (IU/L)
18 (14-35) 15 (12-21) 15 (12-22) 20 (14-30)
Treatment Isoniazid, Rifampicin - 43 (48%) - -
Isoniazid - 26 (30%) - -
Rifampicin - 18 (20%) - -
Moxifloxacin - 1 (1%) - -
Rifampicin, Azithromycin - 1 (4%) -
Rifampicin, Clarithromycin - - 3 (12%) -
Rifampicin, Clarithromycin, Amikacin - - 1 (4%) -
Rifampicin, Ethambutol - - 1 (4%) -
Rifampicin, Ethambutol, Amikacin - - 1 (4%) -
Rifampicin, Ethambutol, Clarithromycin - - 15 (60%) -
Rifampicin, Ethambutol, Moxifloxacin - - 1 (4%) -
Rifabutin, Clarithromycin, Moxifloxacin - - 1 (4%) -
Clarithromycin, Clofazimine, Azithromycin - - 1 (4%) -
Isoniazid, Rifampicin, Pyrazinamide, Ethambutol plus ART - - - 64 (100%)
Initiation phase Isoniazid, Rifampicin, Pyrazinamide, Ethambutol 22 (73%) - - -
Isoniazid, Rifampicin, Pyrazinamide, Moxifloxacin 1 (3%) - - -
Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, Moxifloxacin 1 (3%) - - -
Isoniazid, Rifabutin, Pyrazinamide, Ethambutol 1 (3%) - - -
Isoniazid, Rifampicin, Ethambutol, Moxifloxacin 3 (10%) - - -
Rifampicin, Ethambutol, Moxifloxacin 1 (3%) - - -
Bedaquiline, Clofazimine, Cycloserine 1 (3%) - - -
Continuation phase Isoniazid, Rifampicin 20 (67%) - - -
Isoniazid, Rifampicin, Moxifloxacin 2 (7%) - - -
Isoniazid, Rifampicin, Ethambutol 2 (7%) - - -
Isoniazid, Rifabutin, Moxifloxacin 1 (3%) - - -
Isoniazid, Ethambutol, Moxifloxacin 1 (3%) - - -
Isoniazid, Rifampicin, Pyrazinamide, Ethambutol 1 (3%) - - -
Rifampicin, Ethambutol, Moxifloxacin 2 (7%) - - -
Bedaquiline, Clofazimine, Cycloserine 1 (3%) - - -